CBP-1008 

CBP-1008 is a dual-ligand peptide-drug conjugate (PDC) conjugated to MMAE (HY-15162), targeting Folate receptor α (FRα) and TRPV6. CBP-1008 binds to FRα with high affinity and TRPV6 with low affinity. CBP-1008 has antitumor activity, and can be used in advanced solid tumor research (eg: colorectal cancer, breast cancer, non-small cell lung cancer, ovarian cancer, adrenocortical carcinoma and follicular dendritic cell sarcoma)^[1][2][3].

CBP-1008 shows faster FRα-mediated internalization and cytotoxicity in the presence of TRPV6 than in the absence of TRPV6^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CBP-1008 retains and accumulates in tumors with a half-life of over 48 hours^[3].
CBP-1008 has an MTD of 4 mg/kg in mice, 2 mg/kg in rats, and 1 mg/kg in monkeys^[3].
CBP-1008 shows better efficacy in FRα- and TRPV6-positive than in at least one marker-negative ovarian PDX tumors, as well as growth inhibition of FRα⁺/TRPV6⁺ tumors closely correlates with IHC score^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Fu, et al. Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?. Acta pharmaceutica Sinica. B. 2023, 13(2), 498–516.  [Content Brief]

  [2]. Gong, et al. First-in-human, phase I study of CBP-1008, a bi-specific ligand drug conjugate, in patients with advanced solid tumors. Journal of Clinical Oncology. 2023, 41 (16).

  [3]. Tan, et al. CBP-1008 shows excellent efficacy and desirable drug safety profile in preclinical models. Proceedings of the American Association for Cancer Research Annual Meeting 2022. 2022, 82(12_Suppl).